e-learning
resources
ERJ
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance
Armand Van Deun, Chen-Yuan Chiang
Source:
Eur Respir J, 49 (6) 1700223; 10.1183/13993003.00223-2017
Journal Issue:
June
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Armand Van Deun, Chen-Yuan Chiang. Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance. Eur Respir J, 49 (6) 1700223; 10.1183/13993003.00223-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Fluoroquinolone resistance in multidrug-resistant
Mycobacterium tuberculosis
independent of fluoroquinolone use
Source: Eur Respir J, 50 (6) 1701633; 10.1183/13993003.01633-2017
Year: 2017
Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance
Source: Eur Respir J, 50 (1) 1700598; 10.1183/13993003.00598-2017
Year: 2017
Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
Source: Eur Respir J 2016; 48: 582-585
Year: 2016
Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis
Source: Eur Respir J, 57 (4) 2004454; 10.1183/13993003.04454-2020
Year: 2021
Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients
Source: Eur Respir J 2013; 42: 1614-1621
Year: 2013
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Source: Eur Respir J 2008; 31: 1155-1159
Year: 2008
Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB
Source: Eur Respir J 2009; 33: 581-585
Year: 2009
Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis
Source: Eur Respir J 2014; 43: 884-897
Year: 2014
Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis
Source: Eur Respir J 2013; 42: 504-512
Year: 2013
Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes
Source: Eur Respir J 2013; 42: 156-168
Year: 2013
The efficacy of a rifabutin-containing regimen for rifabutin-susceptible multidrug-resistant tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis
Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017
Year: 2017
The individual-tailored treatment regimens for multidrug-resistant tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Rapid molecular detection of rifampicin and isoniazid resistance and identification of mutations in resistant genes of multi-drug resistant tuberculosis (MDR-TB) patients
Source: Annual Congress 2011 - Novel strategies for the diagnosis of tuberculosis
Year: 2011
Resistance profile of drugs composing the “shorter” regimen for multidrug-resistant tuberculosis in Brazil, 2000–2015
Source: Eur Respir J , 49 (4) 1602309; DOI: 10.1183/13993003.02309-2016
Year: 2017
Treating multiple-drug resistant tuberculosis
Source: International Congress 2018 – PG13 Challenges in the treatment of tuberculosis
Year: 2018
Efficacy of empiric chemotherapy regimen in patients with multidrug resistant (MDR) tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 656s
Year: 2004
A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 722s
Year: 2004
The efficacy of interferon-alpha in treating multi-drug resistant tuberculosis
Source: Annual Congress 2004 - Management of tuberculosis
Year: 2004
Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy
Source: Eur Respir J 2001; 17: 641-646
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept